Skip to main content

Advertisement

Log in

The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The aim was to investigate the prevalence of VKORC1 and CYP2C9 genotypes in patients requiring anticoagulant therapy in two different region’s populations of Turkey. The recent cohort included 292 patients that needed anticoagulant therapy, and who had a history of deep vein thrombosis and/or pulmonary artery thromboembolism. Genomic DNA was isolated from peripheral blood samples and the StripAssay reverse hybridization or Real Time PCR technique was used for genotype analysis. Genotypes for CYP2C9 were detected as follows: 165 (56.5 %) for CYP2C9*1/*1, 67 (23.0 %) for CYP2C9*1/*2, 25 (8.6 %) for CYP2C9*1/*3, 9 (3.0 %) for CYP2C9*2/*2, 21 (7.2 %) for CYP2C9*2/*3, 5(1.7 %) for CYP2C9*3/*3 for CYP2C9 and the allele frequencies were: 0.723 for allele*1, 0.182 for allele*2 and 0.095 for allele*3 respectively. Genotypes for VKORC1 were detected as follows: 64 (21.9 %) for GG, 220 (75.4 %) for GA and 8 (2.7 %) for AA alleles. The G allele frequency was detected as 0.596, and the A allele frequency was 0.404. The VKORC1 1639 G>A and CYP2C9 mutation prevalence and allele frequency of the current results from two different populations (Sivas and Canakkale) showed similarly very variable profiles when compared to the other results from the Turkish population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Spohn G, Geisen C, Luxembourg B, Sittinger K, Seifried E, Bönig H (2011) Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics. Mol Diagn Ther 15(1):13–19

    Article  PubMed  CAS  Google Scholar 

  2. Zhang X, Li L, Ding X, Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 39(8):1433–1439

    Article  PubMed  CAS  Google Scholar 

  3. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH, EU-PACT Study Group (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32(15):1909–1917

    Article  PubMed  Google Scholar 

  4. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB (2007) Couma-Gen investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22):2563–2570

    Article  PubMed  CAS  Google Scholar 

  5. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF (2010) Integration of genetic, clinical, and INR data to refine warfarindosing. Clin Pharmacol Ther 87(5):572–578

    Article  PubMed  CAS  Google Scholar 

  6. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM (2009) Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis 43(1):119–128

    Article  PubMed  CAS  Google Scholar 

  7. Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P (2011) Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics 21(6):344–346

    Article  PubMed  CAS  Google Scholar 

  8. Jorge E, Pêgo JM, Baptista R, Lourenço M, Marques I, Correia A, Monteiro P, Antunes F, Providência LA (2010) Genetic characterization of warfarin sensitivity in a population of cardiovascular patients on chronic anticoagulation. Rev Port Cardiol 29(12):1831–1838

    PubMed  Google Scholar 

  9. Schwartz JB, Kane L, Moore K, Wu AH (2011) Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc 12(9):633–638

    Article  PubMed  Google Scholar 

  10. Stojiljkovic M, Patrinos GP, Pavlovic S (2011) Clinical applicability of sequence variations in genes related to drug metabolism. Curr Drug Metab 12(5):445–454

    Article  PubMed  CAS  Google Scholar 

  11. Baek IH, Kang W, Yun HY, Lee SS, Kwon KI (2011) Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism. J Clin Pharm Ther 36(3):390–398

    Article  PubMed  CAS  Google Scholar 

  12. Stepien E, Branicka A, Ciesla-Dul M (2009) Undas A.A vitamin K epoxide reductase-oxidase complex gene polymorphism (−1639 G>A) and interindividual variability in the dose-effect of vitamin K antagonists. J Appl Genet 50(4):399–403

    Article  PubMed  CAS  Google Scholar 

  13. Flockhart DA, O’Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O’Kane D, Schulman K, Veenstra D, Williams MS (2008) ACMG working group on pharmacogenetic testing of CYP2C9, VKORC1Alleles for warfarin use. Pharmacogenetic testing of CYP2C9 and VKORC1 allelesfor warfarin. Genet Med 10(2):139–150

    Article  PubMed  CAS  Google Scholar 

  14. Sychev DA, Ignat’ev IV, Kropacheva ES, Emel’ianov NV, Milovanova VV, Naumova IuA, Kosovskaia AV, Dobrovol’skiĭ OB, Tashenova AI, Panchenko EP, Kukes VG (2011) CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications. Vestn Ross Akad Med Nauk 3:7–10

    PubMed  Google Scholar 

  15. Lei G, Lei H, Jin L, Bin X, Jie Y, Yu-xiao Z, Ting Y, Ke L, Jin-wen T, Hong-juan W, Yu-sheng Z, Cai-yi L, Wen-zi Z, Tong Y (2011) Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A. Chin Med J 124(17):2767–2770

    Google Scholar 

  16. Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ, Kim S, Lee SY, Ki CS, Osman IM, Rhman EA, Ali IA, Idris MN, Kim JW (2011) Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 67(11):1119–1130

    Article  PubMed  CAS  Google Scholar 

  17. Gan GG, Phipps ME, Lee MM, Lu LS, Subramaniam RY, Bee PC, Chang SH (2011) Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 90(6):635–641

    Article  PubMed  CAS  Google Scholar 

  18. Garcia AA, Reitsma PH (2008) VKORC1 and the vitamin K cycle. Vitam Horm 78:23–33

    Article  PubMed  CAS  Google Scholar 

  19. Vein J, Grandemange A, Cosson JF, Benoit E, Berny PJ (2011) Are water vole resistant to anticoagulant rodenticides following field treatments? Ecotoxicology 20(6):1432–1441

    Article  PubMed  CAS  Google Scholar 

  20. Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH (2011) Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 56(4):290–295

    Article  PubMed  CAS  Google Scholar 

  21. Mitchell C, Gregersen N, Krause A (2011) Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12(7):953–963

    Article  PubMed  CAS  Google Scholar 

  22. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ (2011) The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89(3):408–415

    Article  PubMed  CAS  Google Scholar 

  23. Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS (2011) Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet 6(12):80

    Article  Google Scholar 

  24. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11(6):781–791

    Article  PubMed  CAS  Google Scholar 

  25. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB (2011) Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90(4):625–629

    Article  PubMed  CAS  Google Scholar 

  26. Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F (2010) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessel 25(2):155–162

    Article  Google Scholar 

  27. Yang J, Huang C, Shen Z, Miao L (2011) Contribution of 1173 C>T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. Int J Clin Pharmacol Ther 49(1):23–29

    PubMed  CAS  Google Scholar 

  28. Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP (2010) The c.−1639 G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis 21(6):558–563

    Article  PubMed  Google Scholar 

  29. Vorob’eva NM, Panchenko EP, Dobrovol’skiĭ AB, Titaeva EV, Khasanova ZB, Konovalova NV, Postnov AIu, Kirienko AI (2011) Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage. Ter Arkh 83(6):59–65

    PubMed  Google Scholar 

  30. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M (2011) VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12(1):15–25

    Article  PubMed  CAS  Google Scholar 

  31. Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B (2010) Frequencies of VKORC1 −1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends 4(6):333–337

    PubMed  CAS  Google Scholar 

  32. Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F (2010) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessel 25(2):155–162

    Article  Google Scholar 

  33. Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, Hatemi AC, Siva A, Saip S, Johnson JA (2008) VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 64(9):889–894

    Article  PubMed  CAS  Google Scholar 

  34. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z, Nacak M, Roots I (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48(3):409–415

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Oztürk Ozdemir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silan, C., Dogan, O.T., Silan, F. et al. The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. Mol Biol Rep 39, 11017–11022 (2012). https://doi.org/10.1007/s11033-012-2004-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-2004-2

Keywords

Navigation